2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold ForeverThe Motley Fool • 10/25/25
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?Zacks Investment Research • 10/24/25
Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend DogsSeeking Alpha • 10/24/25
Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSRBusiness Wire • 10/23/25
These low-risk stocks could be a profitable answer to this volatile earnings seasonMarket Watch • 10/23/25
Investment Firm Verity & Verity Loads Up With 908,000 Pfizer (PFE) Shares Worth $22.4 MillionThe Motley Fool • 10/23/25
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based TherapyGlobeNewsWire • 10/20/25
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate CancerBusiness Wire • 10/19/25
Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung CancerBusiness Wire • 10/19/25
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patientsReuters • 10/18/25